113 related articles for article (PubMed ID: 20202838)
21. 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
Whitehead JW; Lee GP; Gharagozloo P; Hofer P; Gehrig A; Wintergerst P; Smyth D; McCoull W; Hachicha M; Patel A; Kyle DJ
J Med Chem; 2005 Feb; 48(4):1237-43. PubMed ID: 15715490
[TBL] [Abstract][Full Text] [Related]
22. Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.
Guo J; Watson A; Kempson J; Carlsen M; Barbosa J; Stebbins K; Lee D; Dodd J; Nadler SG; McKinnon M; Barrish J; Pitts WJ
Bioorg Med Chem Lett; 2009 Apr; 19(7):1935-8. PubMed ID: 19272774
[TBL] [Abstract][Full Text] [Related]
23. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
[TBL] [Abstract][Full Text] [Related]
24. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
[TBL] [Abstract][Full Text] [Related]
25. PDE4 inhibitors - a review of the current field.
Press NJ; Banner KH
Prog Med Chem; 2009; 47():37-74. PubMed ID: 19328289
[No Abstract] [Full Text] [Related]
26. Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
Brullo C; Massa M; Rocca M; Rotolo C; Guariento S; Rivera D; Ricciarelli R; Fedele E; Fossa P; Bruno O
J Med Chem; 2014 Aug; 57(16):7061-72. PubMed ID: 25126889
[TBL] [Abstract][Full Text] [Related]
27. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Kodimuthali A; Jabaris SS; Pal M
J Med Chem; 2008 Sep; 51(18):5471-89. PubMed ID: 18686943
[No Abstract] [Full Text] [Related]
28. Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design.
Srivani P; Usharani D; Jemmis ED; Sastry GN
Curr Pharm Des; 2008; 14(36):3854-72. PubMed ID: 19128237
[TBL] [Abstract][Full Text] [Related]
29. A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
Chambers RJ; Abrams K; Castleberry TA; Cheng JB; Fisher DA; Kamath AV; Marfat A; Nettleton DO; Pillar JD; Salter ED; Sheils AL; Shirley JT; Turner CR; Umland JP; Lam KT
Bioorg Med Chem Lett; 2006 Feb; 16(3):718-21. PubMed ID: 16263279
[TBL] [Abstract][Full Text] [Related]
30. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
31. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
33. Optimization and validation of a reporter gene assay for screening of phosphodiesterase inhibitors in a high throughput system.
Nanda K; Chatterjee M; Arya R; Mukherjee S; Saini KS; Dastidar S; Ray A
Biotechnol J; 2008 Oct; 3(9-10):1276-9. PubMed ID: 18655041
[TBL] [Abstract][Full Text] [Related]
34. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
[TBL] [Abstract][Full Text] [Related]
35. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
[TBL] [Abstract][Full Text] [Related]
36. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
37. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
Card GL; Blasdel L; England BP; Zhang C; Suzuki Y; Gillette S; Fong D; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
Nat Biotechnol; 2005 Feb; 23(2):201-7. PubMed ID: 15685167
[TBL] [Abstract][Full Text] [Related]
38. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for the activity of drugs that inhibit phosphodiesterases.
Card GL; England BP; Suzuki Y; Fong D; Powell B; Lee B; Luu C; Tabrizizad M; Gillette S; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
Structure; 2004 Dec; 12(12):2233-47. PubMed ID: 15576036
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
